toxylact: a04ad05 metopimazine
The first professional lActological database in the word
Metopimazine (ATC A04AD05) is a phenothiazine antiemetic that acts predominantly as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone and peripheral D2 sites, and its use in lactation requires a cautious, individualized risk–benefit assessment due to limited direct human data.medpedia.framar+4
Pharmacological class and indications
Metopimazine belongs to the phenothiazine
group of antiemetics,
with prominent antidopaminergic activity.sciencedirect+3
Clinically it is used to prevent and treat nausea and
vomiting, particularly
chemotherapy‑induced nausea and vomiting (CINV), acute
gastroenteritis–related
emesis, postoperative nausea, and other gastrointestinal
disorders causing
nausea.synapse.patsnap+3
Metopimazine is marketed in Europe, Canada and South America under brand names such as Vogalene/Vogalen, with multiple oral, rectal and intravenous formulations, and is an active ingredient in nationally approved medicinal products though not centrally approved by EMA or FDA.guidetopharmacology+1
Mechanism of action and pharmacodynamics
Metopimazine exerts its antiemetic effect
primarily through
antagonism of dopamine D2 receptors in the chemoreceptor
trigger zone (CTZ) and
at peripheral D2 sites in the gastrointestinal tract.synapse.patsnap+3
By blocking D2 receptors, it reduces CTZ activation by
emetogenic stimuli and
modulates gastrointestinal motility, thereby diminishing the
intensity and
frequency of nausea and vomiting.medpedia.framar+2
Experimental and clinical pharmacology also indicate some affinity for serotonin 5‑HT3 and histamine H1 receptors, which may contribute to its broader antiemetic profile and sedation potential.synapse.patsnap+1
Pharmacokinetics and formulations
Metopimazine is available as capsules, orally
disintegrating
tablets, suppositories, oral liquid, and intravenous
solution, allowing
flexible use in ambulatory and oncology settings.wikipedia
The approved daily dose in French oral products is typically
around 30 mg/day,
divided into multiple doses, with IV formulations used
mainly for CINV in
adults and children.sciencedirect+1
Pediatric pharmacokinetic data show that orally administered metopimazine achieves plasma concentrations compatible with antiemetic efficacy in children with acute gastroenteritis, supporting its frequent clinical use in this population.bpspubs.onlinelibrary.wiley
Efficacy and clinical use
In chemotherapy‑induced nausea and vomiting,
adding metopimazine
to ondansetron or ondansetron plus prednisolone
significantly increases the
proportion of patients with no acute emesis compared with
ondansetron alone,
with response rates around 63–78% versus 47–50% for
monotherapy.sciencedirect
Metopimazine combined with prednisolone appears less
effective than granisetron
in some acute CINV settings, but still provides clinically
meaningful
antiemetic protection.sciencedirect
Beyond CINV, metopimazine is widely prescribed in France for general nausea and vomiting, including pregnancy‑related emesis and gastroenteritis, reflecting its established position as a dopamine‑blocking antiemetic.pubmed.ncbi.nlm.nih+1
Adverse effects and toxicity profile
Documented adverse reactions include allergic
reactions with rash
or urticaria, extrapyramidal symptoms such as parkinsonism,
dystonia and rarely
malignant neuroleptic syndrome, sedation, endocrine
disturbances (gynecomastia
in men, galactorrhea and amenorrhea in women), hypotension,
blurred vision,
photophobia, constipation and urinary retention.medpedia.framar+1
In clinical experience, sedation, orthostatic hypotension
and anticholinergic
effects are among the more commonly reported adverse events,
while
extrapyramidal dyskinesias are described as uncommon but
potentially serious.medpedia.framar+1
As a phenothiazine derivative, metopimazine shares class‑related neuroleptic and endocrine risks, including the potential for hyperprolactinemia and neuroleptic malignant syndrome, particularly at higher doses or in susceptible patients.guidetopharmacology+2
Pregnancy and reproductive safety
A large observational cohort using the
EFEMERIS database
evaluated 135,574 pregnant women, of whom 11,402 (8.2%) were
exposed to
metopimazine, predominantly in the first trimester.pubmed.ncbi.nlm.nih
No association was found between first‑trimester exposure
and major birth
defects (adjusted odds ratio approximately 1.06, 95% CI
0.92–1.23), and
pregnancy loss was actually negatively associated with
metopimazine use
(adjusted hazard ratio about 0.80, 95% CI 0.72–0.88).pubmed.ncbi.nlm.nih
Rates of prematurity, low birth weight and small‑for‑gestational‑age infants were comparable between exposed and unexposed women, and the authors concluded that available data do not indicate a teratogenic effect or increased risk of pregnancy loss, while emphasizing that formal efficacy and safety trials in pregnant women remain lacking.pubmed.ncbi.nlm.nih
Lactation: general principles and extrapolated risk
There are currently no robust, direct
quantitative data on
metopimazine excretion into human breast milk or systematic
lactation safety
studies for this specific drug.sps+1
However, its pharmacological class, molecular
characteristics and clinical
experience with related dopamine‑blocking antiemetics (e.g.,
metoclopramide,
phenothiazines such as prochlorperazine and promethazine)
inform a cautious,
extrapolated toxicological‑lactological assessment.e-lactancia+2
For several antiemetics, short‑term use in breastfeeding is considered acceptable with careful monitoring of the infant for sedation, gastrointestinal symptoms and feeding difficulties, and with attention to maternal safety (e.g., extrapyramidal effects and mood changes).nhs+1
Potential effects on the breastfed infant
Based on its mechanism and class, potential infant risks from metopimazine exposure via breast milk include:
· Central nervous system depression: drowsiness, decreased arousal, or impaired feeding behavior, related to D2 antagonism and sedative H1 activity.sps+3
· Extrapyramidal or neuromotor effects: theoretically dystonia, abnormal movements or altered tone, although such events are rare even with therapeutic infant doses of dopamine antagonists.sps+2
· Gastrointestinal symptoms: possible constipation or mild digestive discomfort related to anticholinergic effects and dopaminergic modulation of gut motility, similar to occasional GI complaints reported with metoclopramide in breastfed infants.nhs+2
Given the lack of quantitative milk transfer data for metopimazine, any suspected infant effect (excessive sleepiness, poor feeding, abnormal movements, or persistent GI symptoms) should prompt immediate clinical review and reconsideration of therapy.nhs+1
Potential effects on lactation and maternal endocrine status
Phenothiazine dopamine antagonists can raise
serum prolactin,
potentially promoting or sustaining lactation in some women,
but the clinical
magnitude and consistency of this effect with metopimazine
are not
characterized.e-lactancia+3
Conversely, chronic dopamine blockade may contribute to
menstrual disturbances,
galactorrhea and other endocrine phenomena, which could
complicate lactation
and maternal reproductive health if high doses or long‑term
courses are used.e-lactancia+2
Because other dopamine‑blocking agents such as metoclopramide have been deliberately used as galactagogues but later discouraged due to maternal and infant risk concerns, any extrapolated use of metopimazine to influence milk production should be avoided outside specialist supervision.e-lactancia+1
Clinical use in breastfeeding mothers: risk–benefit framework
For breastfeeding women with severe nausea and vomiting (e.g., CINV, postoperative nausea, or severe gastroenteritis) where metopimazine is being considered, the following principles can guide risk–benefit evaluation:
· Indication and necessity: reserve metopimazine for situations where non‑pharmacological measures and safer, better‑studied antiemetics in lactation are ineffective or unsuitable, and where effective emesis control is critical to maternal health and continuation of breastfeeding.sps+1
· Dose and duration: use the lowest effective dose for the shortest feasible duration to minimize cumulative infant exposure via breast milk, avoiding prolonged or high‑dose therapy whenever possible.wikipedia+2
· Infant factors: avoid or be extremely cautious in preterm or medically fragile infants, in whom CNS depression or extrapyramidal toxicity would be less tolerable, and prefer alternative antiemetics with more favorable lactation data.sps
Routine co‑sleeping should be avoided when the mother uses sedating medications due to increased risk of sudden unexpected death in infancy, a precaution that applies to metopimazine as a potentially sedating phenothiazine antiemetic.sps
Lactation‑oriented monitoring and counselling
If metopimazine is used during breastfeeding, targeted monitoring should be implemented:
· Infant monitoring: observe for changes in feeding pattern, weight gain trajectory, alertness, unusual sleepiness, abnormal movements, or gastrointestinal symptoms such as constipation or abdominal discomfort; promptly reassess therapy if such signs appear.nhs+1
· Maternal monitoring: screen for extrapyramidal symptoms, mood changes, sedation, orthostatic hypotension and endocrine disturbances (e.g., galactorrhea, menstrual irregularities), and adjust dose or consider switching to an alternative antiemetic as needed.medpedia.framar+2
Counselling should emphasize that the evidence base for metopimazine in lactation is limited, that safer alternatives may exist depending on indication, and that shared decision‑making with the patient is essential, especially in oncology or complex medical contexts.sciencedirect+1
Preferred alternatives and positioning in lactation safety
Current lactation guidance for antiemetics
(based largely on UK
NHS specialist pharmacy service recommendations) highlights
several agents with
more characterized breastfeeding safety profiles, such as
cyclizine, hyoscine
hydrobromide, metoclopramide, ondansetron, prochlorperazine
and promethazine,
used short‑term with caution and infant monitoring.nhs+1
Metopimazine, lacking comparable lactation data, should
generally be considered
a second‑line or specialist‑use option in breastfeeding,
reserved for cases
where its particular efficacy or clinical familiarity
outweighs the
uncertainties regarding infant exposure.guidetopharmacology+2
From a toxicological‑lactological perspective, metopimazine fits into the broader category of dopamine‑blocking antiemetics requiring individualized assessment, careful dosing and structured monitoring when used in breastfeeding mothers, rather than routine first‑line selection.medpedia.framar+2



